WO1988007376A1 - Remedy for viral diseases - Google Patents
Remedy for viral diseases Download PDFInfo
- Publication number
- WO1988007376A1 WO1988007376A1 PCT/JP1988/000223 JP8800223W WO8807376A1 WO 1988007376 A1 WO1988007376 A1 WO 1988007376A1 JP 8800223 W JP8800223 W JP 8800223W WO 8807376 A1 WO8807376 A1 WO 8807376A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- viral diseases
- remedy
- receptor
- drugs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a remedy for viral diseases.
- Viruses can infect cells because the antigenic structure of the virus's infectious group has been created such that it binds to the antigenic structure on the surface of the virus receptor. is there.
- the present invention utilizes the above properties.
- the free virus receptor administered to a patient with viral disease binds to the infectious group of virus and neutralizes the virus in the patient.
- the HIV virus binding site of the T4 receptor or the T4 receptor is isolated by a method such as rafting and administered to AIDS patients by parenteral means, for example, by infusion.
- the present invention makes it possible to use a therapeutic agent having an effect of specifically inhibiting infection with a virus having antigenic variability, for example, HIV virus.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
A remedy for viral diseases comprising a solubilized virus receptor as the effective ingredient. This medicine utilizes the adsorbability of viruses by virus receptors.
Description
明 細 害 Harm
ウ ィ ル ス 病 治 療 薬 Drugs for treating viral diseases
技 術 分 野 Technical field
本発明はウ ィ ルス病治療薬に関す る 。 The present invention relates to a remedy for viral diseases.
背 景 技 術 Background technology
·ウ ィ ルス病治療薬に関す る。 · Regarding drugs for treating viral diseases.
従来ウ ィ ルス病には有効な治療薬は殆どな く 有効と認め られ たわずかな薬品、 例えば A Z T な どの薬品も強い副作用な ど の問題点のため殆ど使用されていなか っ た。 そ こ でウ ィ ルス に対す る モ ノ ク ローナル抗体の投与に よ る ウ ィ ル スのみを特 異的に攻撃す る方法も知 ら れて い たが、 レ ンチウ ィ ルス科の ウ ィ ルス、 例えばエ イ ズウ イ ルスな どの表面抗原が患者体内 において急速に変異する ゥ イ ノレス にはす'ベての変異ウ ィ ルス に結合する中和抗体が発見されないため応用が困難であ っ た 発 明 の 開 示 Heretofore, few effective drugs have been found to be effective for viral diseases, and few drugs that have been found to be effective, such as AZT, have hardly been used due to problems such as strong side effects. Therefore, a method of specifically attacking only the virus by administering a monoclonal antibody to the virus was known, but a virus of the Lentivirus family was also known. Surface antigens such as E. coli virus are rapidly mutated in the patient body.It is difficult to apply innoles because neutralizing antibodies that bind to all mutated viruses are not found. Disclosure of the invention
ウ ィ ルスが細胞に感染 し う る のはウ ィ ルスの感染基の抗原構 造がウ ィ ルス レ セプタ ーの表面の抗原構造に結合す る よ う -に つ く ら れてい る ためであ る。 Viruses can infect cells because the antigenic structure of the virus's infectious group has been created such that it binds to the antigenic structure on the surface of the virus receptor. is there.
本発明は上記の性質を利用す る ものであ る。 The present invention utilizes the above properties.
ウ ィ ルス病患者体内に投与された 、 遊離ウ ィ ルス レ セプタ ー は、 患者体内において 、 ウ ィ ルスの感染基と結合 し そのウ イ ルス を中和す る 。 The free virus receptor administered to a patient with viral disease binds to the infectious group of virus and neutralizes the virus in the patient.
発明を実施す る ための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
本発明 をエ イ ズ治療に使用す る場合の一実施例について説明 す る 。 An example in which the present invention is used for treating AIDS will be described.
T 4 レ セプタ ーを持つ細胞、 例えば T 4細胞な ど よ り 、 モ ノ ク ロ 一寸ル抗体を使用 し た ィ ム ノ ア フ ィ ニチ イ一ク ロマ ト グ Immunochromatography using monoclonal antibodies to cells with T4 receptors, such as T4 cells
新たな用
ラフ ィ 一などの方法で、 T 4 レセプタ一も し く は T 4 レセプ ターの H I Vウ ィルス結合部位を単離し、 エイズ患者に非経 口的手段、 例えば点滴などによ って投与する。 New use The HIV virus binding site of the T4 receptor or the T4 receptor is isolated by a method such as rafting and administered to AIDS patients by parenteral means, for example, by infusion.
産業上の利用可能性 Industrial applicability
以上述べたよ うに、 本発明によって抗原変異性を持つウ ィル ス、 例えば H I Vウ ィルスの感染を特異的に阻害する効果を 持つ治療薬が可能となる。 As described above, the present invention makes it possible to use a therapeutic agent having an effect of specifically inhibiting infection with a virus having antigenic variability, for example, HIV virus.
よって上述のよ うなウ ィルスのもた らす疾病に対して特効薬 となる。
Therefore, it is a silver bullet against the above-mentioned diseases caused by virus.
Claims
1 . 可溶化ウ ィルス レセブターを有効成分とする ウ ィルス病 '冶療薬 1. Virus disease containing a solubilized virus receptor as an active ingredient
2 該ウ ィ ルスがレンチウ ィルスである請求の範囲第一項記 载のウ ィルス病治療薬 2. The remedy for viral diseases according to claim 1, wherein the virus is a lenticular virus.
3 該ウ ィルスが H I Vウ ィルスである請求の範囲第一項記 載のゥ ィ ルス病治療薬 3. The remedy for viral diseases according to claim 1, wherein said virus is HIV virus.
新た な用紙
New paper
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP1988/000223 WO1988007376A1 (en) | 1987-03-27 | 1988-02-29 | Remedy for viral diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62/75065 | 1987-03-27 | ||
| PCT/JP1988/000223 WO1988007376A1 (en) | 1987-03-27 | 1988-02-29 | Remedy for viral diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1988007376A1 true WO1988007376A1 (en) | 1988-10-06 |
Family
ID=13930561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1988/000223 WO1988007376A1 (en) | 1987-03-27 | 1988-02-29 | Remedy for viral diseases |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1988007376A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0385909A2 (en) * | 1989-03-03 | 1990-09-05 | MicroGeneSys, Inc. | A kit or composition for the prevention or treatment of HIV-1 infections |
| EP0832971A1 (en) * | 1987-10-02 | 1998-04-01 | Genentech, Inc. | Adheson variants |
| US6117655A (en) * | 1987-10-02 | 2000-09-12 | Genentech, Inc. | Nucleic acid encoding adhesion variants |
| US6710169B2 (en) | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5375323A (en) * | 1976-12-15 | 1978-07-04 | Mochida Pharm Co Ltd | Unsolublized reseptor and mesuring method by using same |
-
1988
- 1988-02-29 WO PCT/JP1988/000223 patent/WO1988007376A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5375323A (en) * | 1976-12-15 | 1978-07-04 | Mochida Pharm Co Ltd | Unsolublized reseptor and mesuring method by using same |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0832971A1 (en) * | 1987-10-02 | 1998-04-01 | Genentech, Inc. | Adheson variants |
| US6117655A (en) * | 1987-10-02 | 2000-09-12 | Genentech, Inc. | Nucleic acid encoding adhesion variants |
| US6710169B2 (en) | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
| EP0385909A2 (en) * | 1989-03-03 | 1990-09-05 | MicroGeneSys, Inc. | A kit or composition for the prevention or treatment of HIV-1 infections |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cooper et al. | The role of antibody and complement in the control of viral infections | |
| Foster et al. | Are all type I human interferons equivalent? | |
| JP2000500124A (en) | Pharmaceutical for specifically modulating the immune response in the control of viruses, tumors, bacteria and parasites | |
| DE69233607D1 (en) | Peptides that induce the cytotoxic T lymphocyte response to hepatitis B virus | |
| DE69227500D1 (en) | Monoclonal antibodies useful in the therapy of HIV-1 infection | |
| Bretscher et al. | Vaccination against and treatment of tuberculosis, the leishmaniases and AIDS: perspectives from basic immunology and immunity to chronic intracellular infections | |
| WO1988007376A1 (en) | Remedy for viral diseases | |
| US5658569A (en) | Anti-HIV-1 neutralizing antibodies | |
| US7070785B2 (en) | Heat shock proteins for use in enhancing cellular factor production | |
| Sjölander et al. | Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-ISCOM preparations. A comparison with other adjuvant systems | |
| EP0385909B1 (en) | A kit or composition for the prevention or treatment of HIV-1 infections | |
| Harty et al. | Monoclonal antibody protection from age-dependent poliomyelitis: implications regarding the pathogenesis of lactate dehydrogenase-elevating virus | |
| EP0328390B1 (en) | Peptide treatment of refractory infectious diseases | |
| KR970005325B1 (en) | Aids-preventing, curing agents and the composition for treating thereof | |
| EP0658119B1 (en) | New hiv-1 isolates of a subtype and its differential diagnosis, vaccine against hiv-1 infection of this subtype and process for preparing and using the hiv-1 isolate | |
| SAIFUDDIN et al. | HTLV-I activates complement leading to increased binding to complement receptor-positive cells | |
| CA1292691C (en) | Method for the effective treatment of disease conditions in humans associated with htl virus infection | |
| KR920700698A (en) | Acanthus antiviral protein-monoclonal antibody conjugate | |
| ATE284709T1 (en) | VIRAL CHIMERAS FROM CAEV AND HIV-1 GENETIC ELEMENTS | |
| JPH05262653A (en) | Therapeutic composition of acquired immunodeficiency syndrome (aids) | |
| US5019557A (en) | Method for the effective treatment of disease conditions in humans associated with HTLV-III infection | |
| Kitchen | Effect of diethylcarbamazine on cats given feline leukaemia virus vaccine | |
| JPH01104020A (en) | Remedy for viral disease | |
| JPS63275526A (en) | Hiv virus neutralizing antibody | |
| CN1339318A (en) | Method for treating AIDS and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1988902918 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1988902918 Country of ref document: EP |